Diagnostic Salivary Estradiol ELISA Kit (FDA, CE Mark)

Salimetrics Assay #1-4702 (in vitro diagnostic use)

The Salimetrics Salivary Estradiol (17-beta estradiol, oestradiol) Enzyme Immunoassay Kit was specifically designed to standardize the detection of estradiol in saliva samples for research and biomedical laboratories. Using a small sample volume, this assay kit has an extended range that spans the expected estradiol levels found in human saliva. The average inter- and intra-assay precision coefficients of variation are low with no deleterious matrix effects often found in saliva which are characterized through dilution- and spike-recovery validation procedures. This estradiol assay kit has also been formatted to minimize cross reactivity for related steroids.Estradiol (17β-estradiol, E2, 1,3,5(10)-estratriene-3, 17β-diol) is the most active naturally secreted estrogen. In men, estradiol originates in the testes and from extraglandular conversion of androgens. Circulating estradiol levels are relatively high at birth in both males and females, but decrease postnatally. Research concerning estradiol has focused predominantly on reproductive issues such as conception, ovulation, infertility, and menopause. Yet, estradiol affects a diversity of biological processes involved with pubertal and reproductive capacity, establishment and maintenance of pregnancy, infant care, coronary artery disease, immunocompetence, and cancer susceptibility. Estradiol is also believed to affect individual differences in cognitive and socioemotional processes, as well as psychopathology.

Request Advice Add to Study

Technical Summary

Assay Protocol
Download Rev. 01.04.21

Specifications
Catalog#:	1-4702
Regulatory Status:	510(k) Exempt, CE Mark
Format:	96-well plate
Assay Time:	~ 3 hrs
Sample Volume/Test:	100 µL
Sensitivity:	0.1 pg/mL
Assay Range:	1 pg/mL - 32 pg/mL
Storage Requirements:	2-8°C

Tests Per Kit
Singlet:	76
Duplicate:	38

Target Analyte
Salivary Estradiol

Technical Documentation
Stop Solution SDS

References & Salivary Estradiol Research

1. Abraham, G.E. (1975). The applications of steroid radioimmunoassay to gynecologic endocrinology. In: Taymor, M.L. and Green, T.H. (eds.): Progress in gynecology, Vol. 1, 111-144. New York: Grune and Stratton.
2. Faiman, C., Winter, S.D., & Reyes, F.I. (1976). Patterns of gonadotropins and gonadal steroids throughout life. Clin Obstet Gynecol, 3(3), 467-483.
3. Kirschner, M.A., Schneider, G., Ertel, N.H., Worton, E. (1982). Obesity, androgens, estrogens, and cancer risk. Cancer Res, 42 (8 suppl), 3281s-3285s.
4. Labrie, F., Bélanger, A., Cusan, L., Candas, B. (1997). Physiological changes in dehydroepiandrosterone are not reflected by serum levels of active androgens and estrogens but of their metabolites: Intracrinology. J Clin Endocrinol Metab, 82(8), 2403-9.
5. Lipson, S.F., & Ellison, P.T. (1996). Comparison of salivary steroid profiles in naturally occurring conception and non-conception cycles. Hum Reprod, 11(10), 2090-96.
6. Choe, J.K., Khan-Dawood, F.S., Dawood, M.Y. (1982). Progesterone and estradiol in saliva and plasma during the menstrual cycle. Am J Obstet Gynecol, 146, 557-62.
7. Bao, A.-M., Liu, R.-Y., van Someren, E.J., et al. (2003). Diurnal rhythm of free estradiol during the menstrual cycle. Eur J Endocrinol, 148(2), 227-32.
8. Chang, R.J., Plouffe Jr., L. Schaffer, K. Physiology of the menopause. In: Comprehensive management of menopause, Lorrain, J., Flouffe Jr., L., Ravnikar, V., Speroff, L., Watts, N., eds. New York: Springer, 1993.
9. Reed, M.J., Lai, L.C., Owen, A.M., et al. (1990). Effect of treatment with 4-hydroxyandrostenedione on the peripheral conversion of androstenedione to estrone and in vitro tumor aromatase activity in postmenopausal women with breast cancer. Cancer Res, 50(1), 193-96.
10. Shirtcliff, E.A., Dahl, R.E., Pollak, S.D. (2009). Pubertal development: Correspondence between hormonal and physical development. Child Dev, 80(2), 327-37.

1. Simpson, E.R. (2000). Role of aromatase in sex steroid action. J Mol Endocrinol, 25(2), 149-56.
2. Winters, S.J., Troen, P. (1986). Testosterone and estradiol are co-secreted episodically by the human testis. J Clin Invest, 78(4), 870-73.
3. Nankin, H.R., Pinto, R., Fan, D.-F., Troen, P. (1975). Daytime titers of testosterone, LH, estrone, estradiol, and testosterone-binding protein: Acute effects of LH and LH-releasing hormone in men. J Clin Endocrinol Metab, 41(2), 271-81.
4. Ouyang, P., Michos, E.D., Kara, R.H. (2006). Hormone replacement therapy and the cardiovascular system: Lessons learned and unanswered questions. J Am College Cardiol, 47(9), 1741-53.
5. McCarthy, M.M. (2008). Estradiol and the developing brain. Physiol Rev, 88(1), 91-134.
6. Balthazart, J., Cornil, C.A., Taziaux, M., et al. (2006). Rapid changes in production and behavioral action of estrogens. Neuroscience, 138(3), 783-91.
7. Karpuzoglu, E., Ahmed, S.A. (2006). Estrogen regulation of nitric oxide and inducible nitric oxide synthase (iNOS) in immune cells: Implications for immunity, autoimmune diseases, and apoptosis. Nitric Oxide, 15(3), 177-86.
8. Colditz, G. A. 1998. Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. J Natl Cancer Inst, 90(11), 814-23.
9. Lépine, J., Audet-Walsh, E., Grégoire, J., et al. (2010) Circulating estrogens in endometrial cancer cases and their relationship with tissular expression of key estrogen biosynthesis and metabolic pathways. J Clin Endocinol Metab, 95(6), 2689-98.
10. Sasano, H., Harada, N. (1998). Intratumoral aromatase in human breast, endometrial, and ovarian malilgnancies. Endocr Rev, 19(5), 593-607.
11. Vining, R.F., & McGinley, R.A. (1987). The measurement of hormones in saliva: Possibilities and pitfalls. J Steroid Biochem, 27(1-3), 81-94.
12. Choe, J.K., Khan-Dawood, F.S., & Dawood, M.Y. (1983). Progesterone and estradiol in saliva and plasma during the menstrual cycle. Am J Obstet Gynecol, 147(5), 557-62.
13. Shirtcliff, E.A., Granger, D.A., Schwartz, E.B., et al. (2000). Assessing estradiol in biobehavioral studies using saliva and blood spots: Simple radioimmunoassay protocols, reliability, and comparative validity. Horm Behav, 38(2), 137-47.
14. Ellison, P.T., Lipson, S.F. (1999). Salivary estradiol–A viable alternative? Fertil Steril, 72(5), 951-52.)

Show Less

How Can we help?

call 800.790.2258

Ask an Expert

Request a Quote

Diagnostic Salivary Estradiol ELISA Kit (FDA, CE Mark)

Salimetrics Assay #1-4702 (in vitro diagnostic use)

Technical Summary

References & Salivary Estradiol Research

How Can we help?

Test Your DBS samples with Salimetrics!